20/20 Biolabs, Inc. (AIDX)
NASDAQ: AIDX · Real-Time Price · USD
0.4231
-0.0035 (-0.82%)
Sep 24, 2026, 4:00 PM EDT - Market closed
20/20 Biolabs Employees
As of December 31, 2025, 20/20 Biolabs had 14 total employees, including 4 full-time and 10 part-time employees. The number of employees decreased by 6 or -30.00% compared to the previous year.
Employees
14
Change
-6
Growth
-30.00%
Revenue / Employee
$145,729
Profits / Employee
-$508,216
Market Cap
5.40M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | -6 | -30.00% | 4 | 10 |
| Sep 30, 2025 | 24 | 4 | 20.00% | 13 | 11 |
| Jun 30, 2025 | 21 | - | - | 13 | 8 |
| Dec 31, 2024 | 20 | -1 | -4.76% | 12 | 8 |
| Dec 31, 2023 | 21 | -9 | -30.00% | 12 | 9 |
| Mar 31, 2023 | 29 | - | - | 16 | 13 |
| Dec 31, 2022 | 30 | - | - | 17 | 13 |
| Dec 31, 2018 | 18 | 6 | 50.00% | 8 | 10 |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Trinity Biotech | 287 |
| WORK Medical Technology Group LTD | 238 |
| Co-Diagnostics | 115 |
| IceCure Medical | 69 |
| Intelligent Bio Solutions | 60 |
| INVO Fertility | 42 |
| enVVeno Medical | 33 |
| Autonomix Medical | 11 |
AIDX News
- 27 days ago - 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - GlobeNewsWire
- 4 weeks ago - 20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - GlobeNewsWire
- 5 weeks ago - 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level - GlobeNewsWire
- 1 month ago - 20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour - GlobeNewsWire
- 1 month ago - 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy - GlobeNewsWire
- 2 months ago - 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock - GlobeNewsWire
- 2 months ago - 20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth - GlobeNewsWire
- 3 months ago - 20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month - GlobeNewsWire